Spyre Therapeutics expands SPY003 license field beyond IBD with dosing restrictions until 2028-2030

Spyre Therapeutics, Inc.

License field expanded from inflammatory bowel disease to all human disease indications.
Monotherapy dosing for non-IBD indications restricted until June 1, 2030; combination until June 1, 2028.
Restrictions may terminate earlier upon a Material Transaction (change of control, asset sale) by June 1, 2028.
Paragon receives non-exclusive license under Spyre's cross-license patents for retained IL-23 antibodies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.